Aura Biosciences (AURA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO and President, with formal business outlined as per the notice and proxy statement.
The meeting was held virtually, with stockholders able to participate and submit questions through an online portal.
Officers, directors, and representatives from the audit firm were introduced.
Board and executive committee updates
Two nominees, David Johnson and Teresa Marie Bitetti, were presented for election as Class 2 directors for a three-year term.
No stockholder nominations for directors were received in advance.
Corporate governance
The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was submitted for ratification.
The audit committee, composed entirely of independent directors, selected the audit firm.
Stockholder ratification of the auditor was sought as a matter of good governance, though not required by bylaws.
Latest events from Aura Biosciences
- Bel-sar's dual-action therapy shows strong early efficacy and safety, supporting a shift in bladder cancer care.AURA
Status Update9 Jul 2026 - Bel-sar achieved 80% tumor control and 90% vision preservation, advancing to Phase 3.AURA
Status Update8 Jul 2026 - Pivotal trials advance in ocular and bladder cancer, targeting large markets with vision-preserving therapies.AURA
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - Vote sought to expand authorized shares and amend equity plan for future growth and flexibility.AURA
Proxy filing29 Jun 2026 - Vote to expand authorized shares and amend the equity plan to support growth and retention.AURA
Proxy filing17 Jun 2026 - Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway.AURA
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA27 May 2026 - Bel-sar targets early, vision-preserving cancer therapy with pivotal data expected by 2027.AURA
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Novel dual-mechanism cancer therapy shows strong efficacy in pivotal ocular and bladder trials.AURA
Corporate presentation11 May 2026 - Firmonertinib and next-gen ADCs drive late-stage oncology pipeline with strong clinical momentum.AURA
Corporate presentation11 May 2026